It also has a Pharmaceutical formulation comprising the anticuerpo.reivindicaci u00f3n 1: isolated an Antibody or fragment that binds to BACE1, where the Antibody reduces or Inhibits the activity of BACE1 polypeptide.Claim 5: Antibody according to claim 1 which comprises at least a sequence selected from the group consisting of HVR - H1, H2 and H3 - HVR HVR, where HVR - H1 comprises the Amino Acid Sequence gfx30fx31x32x33x34ih (SEC ID no. 45), where t = N or X30, X31 = s or, l； X32 = and = or g； and X33 X34 = a or s； and,G s； HVR H2 comprises the Amino Acid Sequence x35x36ispx37x38gx39tx40yadsvkg (SEC ID no. 46), where X35 = 36 = or g； W = o or s； X37 and x38 G S； =； x39 = s or y = d or s and X40 and includes the HVR - H3； Amino Acid Sequence x41px42x43x44x45x46x47mdy (SEC ID no. 47),Where q = X41 X42 = or g； T or F； x43 = H or s； p = x44 X45 and or； OR = and =, V or W； processing and X47 optionally includes the sequence yakgyka (SEC ID no. 48).Claim 54: a method to reduce Amyloid plaques in a patient suffering from, or at risk for a disease or Neurological disorder which comprises administering to the individual an effective amount of the Antibody according to any one of claims 1 - 47.Claim 55: a method to inhibit the formation of Amyloid plaques in a patient suffering from, or at risk of developing a disease or Neurological disorder comprising administering to the individual an effective amount of the Antibody in agreement with any of the claims May 1 - 47.Claim 61: a method to Diagnose a disease or Neurological disorder in a patient that includes contacting a Biological sample from a patient with isolated Antibody according to any one of claims 1 - 47 under appropriate conditions for the Union L Antibody to a polypeptide of BACE1,And detect if there is a complex between the Antibody and the polypeptide of BACE1.Se posee además una formulación farmacéutica que comprende el anticuerpo.Reivindicación 1: Un anticuerpo aislado, o su fragmento, que se une a BACE1, dond
